Single-molecule detection platforms for healthcare and the life sciences.
Electronic data capture for clinical trials and health services research.
Novel transdermal drug delivery patches for higher dose delivery at a constant rate.
Specialist electrophysiological and consultancy services.
Development and production of novel biosensors for the measurement of neuroactive chemicals.
Reformulating a clinical drug to enable use in the treatment of cancer. Preclinical data indicate potential use of the reformulated drug in lung, pancreatic, breast and prostate cancers. Joint venture with Valirx.
Developing ground-breaking therapies for respiratory viral infections. Its pioneering DI platform technology will provide a new class of biological antivirals active across a range of infectious diseases.
|Warwick Effect Polymers/Abzena
Low-viscocity polymers for longer-acting drugs and novel drug targetting. Acquired in 2012 by Polytherics (now Abzena plc)